Poxel (POXEL) Corporate presentation summary

Mission and strategic focus

• Dedicated to developing innovative therapies for chronic and rare metabolic diseases, with a focus on underlying metabolic pathophysiology.

• Strategic emphasis on rare metabolic diseases, particularly ADPKD, ALD, and HCM.

• Experienced management team with proven drug development and partnership capabilities.

Pipeline and clinical development

• PXL770 is a direct AMPK activator targeting ADPKD and ALD, with orphan and fast track designations; clinical PoC trial in ADPKD is being prepared.

• PXL065, a deuterium-stabilized pioglitazone, is being developed for HCM and ALD, showing positive preclinical results in HCM and ALD models.

• TWYMEEG (Imeglimin) is approved and marketed in Japan for type 2 diabetes, with ongoing regional partnership discussions outside Japan.

Financial and partnership highlights

• Cash and cash equivalents of EUR 13.1 million as of September 30, 2024.

• Monetized future TWYMEEG royalties for a $50M upfront payment from OrbiMed, with rights to royalties returning after OrbiMed receives $100M.

• Debt restructuring reduced obligations to IPF Partners and PGE banks, with remaining debt totaling EUR 15.3 million.